β2-Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 6, 2013, Pages 1093-1102

  Pozzi, N ^a,c   Acquasaliente, L ^a   Frasson, R ^a   Cristiani, A ^a   Moro, S ^a   Banzato, A ^a   Pengo, V ^a   Scaglione, G L ^b   Arcovito, A ^b   De Cristofaro, R ^b   De Filippis, V ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 glycoprotein I; Antiphospholipid syndrome; Hemostasis; Surface plasmon resonance; Thrombin

Indexed keywords

4 AMINOBENZAMIDINE; BETA2 GLYCOPROTEIN 1; ENZYME; FIBRIN; PROCOAGULANT; PROTEIN C; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN;

ARTICLE; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HYDROLYSIS; IC 50; IMMUNOCYTOCHEMISTRY; MOLECULAR MODEL; MUTATION; POINT MUTATION; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE AGGREGATION; WILD TYPE;

Β2-GLYCOPROTEIN I; ANTIPHOSPHOLIPID SYNDROME; HEMOSTASIS; SURFACE PLASMON RESONANCE; THROMBIN;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BENZAMIDINES; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; CATALYTIC DOMAIN; CHROMATOGRAPHY, GEL; COAGULANTS; ENZYME INHIBITORS; FIBRIN; FLOW CYTOMETRY; HEMOSTASIS; HIRUDINS; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; KINETICS; MUTATION; NEPHELOMETRY AND TURBIDIMETRY; PROTEIN BINDING; RECEPTOR, PAR-1; SURFACE PLASMON RESONANCE; THROMBIN;

EID: 84883746996     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12238     Document Type: Article

References (34)

1. de Groot PG, Meijers JC. β(2)-Glycoprotein-I: evolution, structure and function. J Thromb Haemost 2011; 9: 1275-84.
2. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta2-glycoprotein-I (apolipoprotein-H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
3. Miyakis S, Giannakopoulos B, Krilis SA. Beta2-glycoprotein-I function in health and disease. Thromb Res 2004; 114: 335-46.
4. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R. Crystal structure of human β2-glycoprotein-I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-39.
5. Hammel M, Kriechbaum M, Gries A, Kostner GM, Laggner P, Prassl R. Solution structure of human and bovine beta(2)-glycoprotein-I revealed by small-angle X-ray scattering. J Mol Biol 2002; 321: 85-97.
6. Agar C, van Os GM, Mörgelin M, Sprenger RR, Marquart JA, Urbanus RT, Derksen RH, Meijers JC, de Groot PG. Beta2-glycoprotein-I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-43.
7. Bode W, Turk D, Karshikov A. The refined 1.9-Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin. Protein Sci 1992; 1: 426-71.
8. Di Cera E. Thrombin as procoagulant and anticoagulant. J Thromb Haemost 2007; 5 (Suppl. 1): 196-202.
9. Esmon CT. The protein-C pathway. Chest 2003; 124 (Suppl. 3): 26S-32S.
10. Huntington JA. Molecular recognition mechanisms of thrombin. J Thromb Haemost 2005; 3: 1861-72.
11. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein-Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001; 276: 4692-8.
12. De Cristofaro R, De Filippis V. The interaction of the 268-282 region of GpIbα with the heparin binding site of thrombin inhibits the enzyme activation of factor VIII. Biochem J 2003; 373: 593-601.
13. Rahgozar S, Yang Q, Giannakopoulos B, Yan X, Miyakis S, Krilis SA. Beta2-glycoprotein-I binds thrombin via exosite-I and exosite-II: anti-beta2-glycoprotein-I antibodies potentiate the inhibitory effect of beta2-glycoprotein-I on thrombin-mediated factor XIa generation. Arthritis Rheum 2007; 56: 605-13.
14. De Filippis V, Vindigni A, Altichieri L, Fontana A. Core domain of hirudin from the leech Hirudinaria manillensis: chemical synthesis and characterization of a Trp3-analog of fragment 1-47. Biochemistry 1995; 34: 9552-64.
15. Lancellotti S, Rutella S, De Filippis V, Pozzi N, Rocca B, De Cristofaro R. Fibrinogen elongated γ-chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors. J Biol Chem 2008; 283: 30193-204.
16. Pozzi N, Banzato A, Bettin S, Bison E, Pengo V, De Filippis V. Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of β2-glycoprotein-I. Protein Sci 2010; 19: 1065-78.
17. Li W, Johnson DJD, Adams TE, Pozzi N, De Filippis V, Huntington JA. Thrombin inhibition by serpins disrupts exosite-II. J Biol Chem 2010; 285: 38621-9.
18. Hofsteenge J, Braun PJ, Stone SR. Enzymatic properties of proteolytic derivatives of human alpha-thrombin. Biochemistry 1988; 27: 2144-51.
19. Evans SA, Olson ST, Shore JD. p-Aminobenzamidine as a fluorescent probe for the active site of serine proteases. J Biol Chem 1982; 257: 3014-17.
20. + binding on the conformation, stability, and molecular recognition properties of thrombin. Biochem J 2005; 390: 485-92.
21. De Cristofaro R, Di Cera E. Phenomenological analysis of the clotting curve. J Protein Chem 1991; 10: 455-68.
22. Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-8.
23. Pozzi N, Barranco-Medina S, Chen Z, Di Cera E. Exposure of R169 controls protein C activation and autoactivation. Blood 2012; 120: 664-70.
24. Ritchie DW, Venkatraman V. Ultra-fast FFT protein docking on graphics processors. Bioinformatics 2010; 26: 2398-405.
25. Pozzi N, Chen Z, Zapata F, Pelc LA, Barranco-Medina S, Di Cera E. Crystal structures of prethrombin-2 reveal alternative conformations under identical solution conditions and the mechanism of zymogen activation. Biochemistry 2011; 50: 10195-202.
26. Machovich R, Borsodi A, Blaskó G, Orakzai SA. Inactivation of alpha- and beta-thrombin by antithrombin-III, alpha 2-macroglobulin and alpha-1-proteinase inhibitor. Biochem J 1977; 167: 393-8.
27. Bianchini EP, Pike RN, Le Bonniec BF. The elusive role of the potential factor-X cation-binding exosite-1 in substrate and inhibitor interactions. J Biol Chem 2004; 279: 3671-9.
28. Agar C, de Groot PG, Mörgelin M, Monk SD, van Os G, Levels JH, de Laat B, Urbanus RT, Herwald H, van der Poll T, Meijers JC. β-glycoprotein-I: a novel component of innate immunity. Blood 2011; 117: 6939-47.
29. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2004; 33: 173-83.
30. Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 2007; 21: 1-11.
31. Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev Physiol 2011; 73: 503-14.
32. Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986; 67: 362-5.
33. Lin F, Murphy R, White B, Kelly J, Feighery C, Doyle R, Pittock S, Moroney J, Smith O, Livingstone W, Keenan C, Jackson J. Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation. Lupus 2006; 15: 87-93.
34. de Laat B, de Groot PG, Derksen RH, Urbanus RT, Mertens K, Rosendaal FR, Doggen CJ. Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood 2009; 114: 3656-61.